DaVita sees limited impact from Ozempic’s kidney trial success, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

The dialysis market has for decades been sustained by high rates of obesity and diabetes, which contribute to kidney damage, but GLP-1 drugs have shown to dramatically improve both conditions., The dialysis market has for decades been sustained by high rates of obesity and diabetes, which contribute to kidney damage, but GLP-1 drugs have shown to dramatically improve both conditions., , Read More

Leave a Reply

Your email address will not be published. Required fields are marked *